Prognostic value of t cell immunoglobulin mucin-3 in prostate cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3897-3901

  Piao, Yong Rui ^a   Piao, Long Zhen ^a   Zhu, Lian Hua ^a   Jin, Zhe Hu ^a   Dong, Xiu Zhe ^a  

^a YANBIAN UNIVERSITY   (China)

Author keywords

Biomarker; Prognosis; Prostate cancer; TIM 3

Indexed keywords

EID: 84882665326     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3897     Document Type: Article

References (16)

1. Abildgaard MO, Borre M, Mortensen MM, et al (2012). Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. Int J Cancer, 130, 885-95.
2. Cai C, Wang L, Wu Z, et al (2012). T-cell immunoglobulin- and mucin-domain- containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA Cell Biol, 31, 1285-9.
3. Facompre N, El-Bayoumy K (2009).Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res, 69, 2699-703.
4. Fourcade J, Sun Z, Benallaoua M, et al (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+T cell dysfunction in melanoma patients. J Exp Med, 207, 2175-86.
5. Geng H, Zhang GM, Li D, et al (2006). Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol, 176, 1411-20.
6. Huang X, Bai X, Cao Y, et al (2010). Lymphoma endothelium preferentially expresses TIM-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med, 207, 505-20.
7. Jan M, Chao MP, Cha AC, et al (2011). Prospective separation of normal and leukemic stem cells based on differential expression of Tim-3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci, 108, 5009-14.
8. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
9. Kikushige Y, Shima T, Takayanagi S, et al (2010). Tim-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell, 7, 708-17.
10. Sakuishi K, Apetoh L, Sullivan JM, et al (2010). Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207, 2187-94.
11. Sugiyama Y, Masumori N, Fukuta F, et al (2013). Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. Asian Pac J Cancer Prev, 14, 1-4.
12. Wiener Z, Kohalmi B, Pocza P, et al (2007). TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol, 127, 906-14.
13. Xu LW, Qian M, Jia RP, et al (2012). Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer. Asian Pac J Cancer Prev, 13, 1639-44.
14. Yang X, Liang L, Zhang XF, et al (2013). MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology, 58, 158-70.
15. Yun UJ, Park SE, Jo YS, Kim J, Shin DY (2012). DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett, 323, 155-60.
16. Zhuang X, Zhang X, Xia X, et al (2012). Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol, 137, 978 - 85.